



Opening remarks

Mattias Häggblom, mattias.haggblom@handelsbanken.se, +46 70 204 40 78

August, 2022

Welcome!

INVITATION FROM HANDELSBANKEN CAPITAL MARKETS

2nd Annual Life Science Innovation Day

With Keynote Speaker Mikael Dolsten, Chief Scientific Officer, Pfizer



The healthcare industry offers many characteristics we like, including tailwinds from demographics, the ability to disrupt through innovative solutions and, often, fragmented market positions, ripe for consolidation. Innovation is one of its core attributes.

Take part in fireside chats with some of the Nordics' most innovative life science companies: **AddLife**, **Arjo**, **Blotage**, **Camurus**, **ChemoMetec**, **Egetis Therapeutics**, **Getinge**, **Hansa Biopharma**, **Medicover**, **Sobi**, **Surgical Science**, **Vitrolife** and **Xvivo**.

We're honored to host **Mikael Dolsten, Chief Scientific Officer, Pfizer** as our Keynote Speaker to discuss innovation and Pfizer's recent accomplishments. There will also be a **panel debate with venture capital members** to discuss emerging technologies.

Date: Wednesday, 24 August, 2022

Time: 08:45 - 16:55 CET

Place: Virtual, link to be provided

Registration: invitations@handelsbanken.se or your local sales contact


Warmly Welcome!

Mattias Häggblom, Rickard Anderkrans, Suzanna Queckbörner

Handelsbanken

For those who don't know me

- M.Sc. Biology University of Stockholm
- 18 years as sell-side analyst, 1997-2015
- Aragon, Alfred Berg and most recently Danske Bank (2007-2015)
- Joined the buy-side and Sweden's largest mutual fund manager, Swedbank Robur 2016-2021 to manage global healthcare fund (AUM\$1bn)
- Returned to sell-side in February 2021 to lead Handelsbanken's efforts within Healthcare equity research



The new Healthcare team



- Rickard Anderkrans
- Joined in early October 2021 from ABG
- MSc, Accounting and finance, Lund
- Student of the year award 2018/19
- Has covered BICO (Cellink), Bonesupport, Photocure
- Will keep medical device/tools profile but also include larger companies



- Suzanna Queckbörner
- Joined in early October 2021 from VC industry
- Novo Holdings in Copenhagen
- PhD from Karolinska Institute
- Has industry experience from Roche and BMS
- Strong profile for therapeutics including pharma&biotech but also trained on reproduction sciences (ie IVF)

The game plan (work in progress) in healthcare

- Hub with 3+ analysts out of Stockholm
- **Söndagsbio (or Handelsbanken's Healthcare Observer)** - a unique weekly email to clients with observations and tidbits to help investors solve the puzzle rather than repeat old research. Please reach out if you're not on the list!
- **Annual Life Science Innovation Day**, last week of August– different format (fireside chats, more in depth discussions)
- **Triple H.** Handelsbanken's Healthy Hour, weekly company fire side chats, Wednesdays 2pm CET, 20-25 meetings per year, virtual, recorded, stored
- Host unique events, that are out of the box (Innovation Index, Access to Medicine etc) and not only yet another quarterly report slide deck
- Team that covers 20-30 Nordic stocks and is the preferred speaking partner

Current coverage – expanding throughout the year

Mattias Häggblom

Contact details



+46 8 7011256
+46 70 204 4078
[Send e-mail >](#)

Companies covered

H O AddLife **B O** Ambu
B O Arjo **H O** AstraZeneca
H O BICO Group **H O** BioGala
H M Biotage **B O** Camurus
H M Chr. Hansen **B O** Coloplast
H M Demant **H O** Elekta
B O GN Store Nord **H O** Genmab
B O Getinge **H M** Lundbeck
H M Novo Nordisk **B O** Photocure
H M Swedish Orphan Biovitrum **H O** Vimian Group

Rickard Anderkrans

Contact details



+46 8 7011995
+46 73 337 4501
[Send e-mail >](#)

Companies covered

B O Ambu **B O** Arjo
H O BICO Group **H O** BioGaia
H M Biotage **H M** Chr. Hansen
B O Coloplast **H M** Demant
H O Elekta **B O** GN Store Nord
B O Gellinge **B O** Photocure
H O Vimian Group

Suzanna Queckbörner

Contact details



+46 8 7011349
[Send e-mail >](#)

Companies covered

H O AstraZeneca **B O** Camurus
H O Genmab **H M** Lundbeck
H M Novo Nordisk **H M** Swedish Orphan Biovitrum

Why differentiated team?

- **Science** background
- **Sell-side** experience
- **Buy-side** experience
- **Industry** experience
- **VC** experience
- **Nomination committee** experience in 3 companies
- And
- **Board member** in private biotech company, Buzzard Pharma (IL-1 blockade) together with serial entrepreneur Thomas Eldered (co-founder Recipharm) and 2 co-founders (who sold previous company Cormorant to BMS)
- =
- Unique (?) speaking partners

Today's format

- Fireside chats – not spending vast majority on quarterly slides you have already seen
- Let's drill down into the key topics in each of the stocks instead of going through Q2 again
- Back-up slides for reference found on the seminar webpage available for download
- Possibility to ask questions by sending e-mail or text message to the moderator
- We hope to enable a productive use of your and the companies time
- Feedback welcome! We'll do it again next year

My 3 favorite sessions

Agenda - Life Science Innovation Day


Agenda:

- 08:45 - 09:00 **Welcome words** – Mattias Häggblom, Sector Head, Healthcare, Handelsbanken
- 09:00 - 09:25 **Sobi** – Guido Oelkers, CEO
- 09:30 - 09:55 **Arjo** – Joacim Lindoff, CEO
- 10:00 - 10:25 **Surgical Science** – Gisli Hennermark, CEO
- 10:30 - 10:55 **ChemoMetec** - Steen Søndergaard, CEO
- 11:00 - 11:25 **Biotage** – Tomas Blomquist, CEO
- 11:30 - 11:55 **Egetis Therapeutics** – Peder Walberg, Board member
- 12:00 - 12:45 **Panel Debate with venture capital members**
- 13:00 - 13:25 **Xvivo** – Dag Andersson, CEO
- 13:30 - 13:55 **Hansa Biopharma** – Christian Kjellman, CSO/COO
- 14:00 - 14:25 **Camurus** – Fredrik Tiberg, CEO
- 14:30 - 14:55 **Vitrolife** – Thomas Axelsson, CEO
- 15:00 - 15:25 **AddLife** – Kristina Willgård, CEO
- 15:30 - 15:55 **Medicover** – Fredrik Rågmark, CEO
- 16:00 - 16:25 **Getinge** – Mattias Perjos, CEO
- 16:30 - 16:55 **Keynote Speaker: Pfizer** – Mikael Dolsten, Chief Scientific Officer

CSO Dr Dolsten, Pfizer joins as this year's guest speaker

Pharmaceutical Innovation

Index 2022



Company	Rank	Change from 2021
Pfizer	1	+7
AstraZeneca	2	+6
Regeneron	3	—
Johnson & Johnson	4*	+11
Merck & Co	4*	+9
BeiGene	6	+21
Takeda	7	+21
BioNTech	8	NEW
Roche	9	-7
Sanofi	10	-3
Bristol Myers Squibb	11	+6
Vertex Pharmaceuticals	12	—
AbbVie	13	+2
Amgen	13	+5
Gilead	15	-5
GlaxoSmithKline	15	-9
Moderna	17	3
Seagen	18	-14
Eli Lilly	19	-18
Novartis	19	-9
UCB	19	NEW
Daichi Sankyo	22	+2
Horizon Therapeutics	23	NEW
Novo Nordisk	23	-10
Bayer	25	+5
Astellas	26	-6
Boehringer Ingelheim	27	+2
Biogen	28	-8
Eisai	29	-10
Shionogi	29	NEW
Merck KGaA	31	-5
Otsuka	32	-1

#1
Pfizer
First in Innovation

+21
BeiGene, Takeda
Most Improved

Innovation: Return on invention; creation of meaningful value from invention.

Note*: Johnson & Johnson and Merck & Co are tied in the ranking

©2022 IDEA Pharma | ideapharma.com

We hope to generate a few new ideas from today's sessions!



Equity research disclaimer

Recommendation structure and allocations

Handelsbanken Capital Markets Equity Research (HCM) employs a four-graded recommendation scale. The recommendations reflect the analyst's assessment of how much the share price may appreciate or depreciate in absolute terms in a 12-month time horizon and takes into account risks related to both fundamental expectations and share performance. This assessment is not based on a proprietary HCM model and the basis for the analyst's assessment is dependent on the characteristics of the sector and the company and a multitude of fundamental and timing factors are incorporated. For more detailed information about the recommendation structure please consult the Handelsbanken Capital Markets website: <https://www.researchonline.se/desc/recstruct>. Investment ratings are determined by the ranges described in the table below. The recommendations do not represent the analyst's or the bank's assessment of the company's fundamental value or quality. The recommendations and absolute performance intervals, together with the allocation of the rating categories amongst companies under coverage and amongst companies under coverage for which Handelsbanken has provided investment banking services in the past 12 months are listed below:

[[Recommendation distribution table](#)]

Source: Handelsbanken Capital Markets, as per [DD/MM/YYYY]

Recommendations are continuously reviewed by the analyst and monitored by the Research Management and will be updated and/or refreshed regularly. The rationale behind a change in recommendation will be explained in such a refresher/update.

A list of all recommendations made by investment research during the preceding 12-month period is available here: <https://www.researchonline.se/desc/rechist>.

The target price (TP) is the analyst's assessment of the level at which the share should be traded in a 12-month period. The TP is used as a basis for the recommendation (see explanation above) and takes into account timing-related issues and triggers, such as relative valuation and newsflow. The TP does not represent the analyst's or the bank's assessment of the company's fundamental value or quality.

Unless otherwise specified, share prices mentioned in this report refer to the closing price of the previous day.

At times, the expected total returns may fall outside of the above stated ranges because of price movement and/or volatility. Such interim deviations from specified ranges will be permitted but will become subject to review by Research

Risk warning

All investments involve risks and investors are encouraged to make their own decision as to the appropriateness of an investment in any securities referred to in this report, based on their specific investment objectives, financial status and risk tolerance. The historical return of a financial instrument is not a guarantee of future return. The value of financial instruments can rise or fall, and it is not certain that you will get back all the capital you have invested. At times, the expected total returns may fall outside of the above stated ranges because of price movement and/or volatility. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management.

Valuation and methodology

Target prices, outlooks and recommendations expressed in this research report are based on a combination of valuation models, such as discounted cash flow (DCF) and relative valuation to peers using ratios such as price-to-earnings (P/E), enterprise-value-to-operating-profit (EV/EBITDA), price-to-book (P/B) and earnings models. Sales and earnings forecasts are based on historical financial data as reported by the company and the analyst's expectations for company-specific performance are derived from expectations of micro- and macroeconomic developments. The company's different business segments are modelled separately in this process and then aggregated to achieve group forecasts for sales, earnings, cash flow and the balance sheet. For more detailed information about the valuation and methodology please consult the Handelsbanken Capital Markets website: <https://www.researchonline.se/desc/disclaimers>

Research disclaimers

Handelsbanken Capital Markets, a division of Svenska Handelsbanken AB (publ) (collectively referred to herein as 'SHB'), is responsible for the preparation of research reports. SHB is regulated in Sweden by the Swedish Financial Supervisory Authority, in Norway by the Financial Supervisory Authority of Norway, in Finland by the Financial Supervisory Authority of Finland and in Denmark by the Danish Financial Supervisory Authority. All research reports are prepared from trade and statistical services and other information that SHB considers to be reliable. SHB has not independently verified such information and does not represent that such information is true, accurate or complete.

In no event will SHB or any of its affiliates, their officers, directors or employees be liable to any person for any direct, indirect, special or consequential damages arising out of any use of the information contained in the research reports, including without limitation any lost profits even if SHB is expressly advised of the possibility or likelihood of such damages.

The views contained in SHB research reports are the opinions of employees of SHB and its affiliates and accurately reflect the personal views of the respective analysts at this date and are subject to change. There can be no assurance that future events will be consistent with any such opinions. Each analyst identified in this research report also certifies that the opinions expressed herein and attributed to such analyst accurately reflect his or her individual views about the companies or securities discussed in the research report.

Research reports are prepared by SHB for information purposes only. The information in the research reports does not constitute a personal recommendation or personalised investment advice and such reports or opinions should not be the basis for making investment or strategic decisions. This document does not constitute or form part of any offer for sale or subscription of or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Past performance may not be repeated and should not be seen as an indication of future performance. The value of investments and the income from them may go down as well as up and investors may forfeit all principal originally invested. Investors are not guaranteed to make profits on investments and may lose money. Exchange rates may cause the value of overseas investments and the income arising from them to rise or fall. This research product will be updated on a regular basis.

No part of SHB research reports may be reproduced or distributed to any other person without the prior written consent of SHB. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

The report does not cover any legal or tax-related aspects pertaining to any of the issuer's planned or existing debt issuances.

Please be advised of the following important research disclosure statements:

SHB employees, including analysts, receive compensation that is generated by overall firm profitability. Analyst compensation is not based on specific corporate finance or debt capital markets services. No part of analysts' compensation has been, is or will be directly or indirectly related to specific recommendations or views expressed within research reports.

From time to time, SHB and/or its affiliates may provide investment banking and other services, including corporate banking services and securities advice, to any of the companies mentioned in our research.

We may act as adviser and/or broker to any of the companies mentioned in our research. SHB may also seek corporate finance assignments with such companies.

We buy and sell securities mentioned in our research from customers on a principal basis. Accordingly, we may at any time have a long or short position in any such securities. We may also make a market in the securities of all the companies mentioned in this report. [Further information and relevant disclosures are contained within our research reports.] SHB, its affiliates, their clients, officers, directors or employees may own or have positions in securities mentioned in research reports.

In conjunction with services relating to financial instruments, the Bank may, under certain circumstances, pay or receive inducements, i.e. fees and commission from parties other than the customer. Inducements may be both monetary and non-monetary benefits. If inducements are paid to or received from a third party, it is required that the payment must aim to improve the quality of the service, and the payment must not prevent the Bank from safeguarding the customer's interests. The customer must be informed about such remuneration that the Bank receives. When the Bank provides investment research, the Bank receives minor non-monetary benefits. Minor non-monetary benefits consist of the following:

- Information or documentation about a financial instrument or an investment service that is general in character.
- Written material produced by a third party that is an issuer to market a new issue.
- Participation at conferences and seminars regarding a specific instrument or investment service
- Corporate hospitality up to a reasonable amount.

The Bank has adopted Guidelines concerning Research which are intended to ensure the integrity and independence of research analysts and the research department, as well as to identify actual or potential conflicts of interests relating to analysts or the Bank and to resolve any such conflicts by eliminating or mitigating them and/or making such disclosures as may be appropriate. As part of its control of conflicts of interests, the Bank has introduced restrictions (“Information barriers”) on communications between the Research department and other departments of the Bank. In addition, in the Bank’s organisational structure, the Research department is kept separate from the Corporate Finance department and other departments with similar remits. The Guidelines concerning Research also include regulations for how payments, bonuses and salaries may be paid out to analysts, what marketing activities an analyst may participate in, how analysts are to handle their own securities transactions and those of closely related persons, etc. In addition, there are restrictions in communications between analysts and the subject company. According to the Bank’s Ethical Guidelines for the Handelsbanken Group, the board and all employees of the Bank must observe high standards of ethics in carrying out their responsibilities at the Bank, as well as other assignments. For full information on the Bank’s ethical guidelines please see the Bank’s website www.handelsbanken.com and click through to About the bank – Sustainability at Handelsbanken – Sustainability – Policy documents and guidelines – Policy documents – Policy for ethical standards in the Handelsbanken Group.

Handelsbanken has a ZERO tolerance of bribery and corruption. This is established in the Bank’s Group Policy on Bribery and Corruption. The prohibition against bribery also includes the soliciting, arranging or accepting bribes intended for the employee’s family, friends, associates or acquaintances. For full information on the Bank’s Policy against corruption please see the Bank’s website www.handelsbanken.com and click through to About the bank – Sustainability at Handelsbanken – Sustainability – Policy documents and guidelines – Policy documents – Policy against corruption in the Handelsbanken Group.

When distributed in the UK

Research reports are distributed in the UK by SHB.

SHB is authorised by the Swedish Financial Supervisory Authority (Finansinspektionen) and the Prudential Regulation Authority and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority. Details about the extent of our authorisation and regulation by the Prudential Regulation Authority, and regulation by the Financial Conduct Authority are available from us on request.

UK customers should note that neither the UK Financial Services Compensation Scheme for investment business nor the rules of the Financial Conduct Authority made under the UK Financial Services and Markets Act 2000 (as amended) for the protection of private customers apply to this research report and accordingly UK customers will not be protected by that scheme.

This document may be distributed in the United Kingdom only to persons who are authorised or exempted persons within the meaning of the Financial Services and Markets Act 2000 (as amended) (or any order made thereunder) or (i) to persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (ii) to high net worth entities falling within Article 49(2)(a) to (d) of the Order or (iii) to persons who are professional clients under Chapter 3 of the Financial Conduct Authority Conduct of Business Sourcebook (all such persons together being referred to as “Relevant Persons”).

When distributed in the United States

Important Third-Party Research Disclosures:

SHB research is not “globally branded” research and each recipient of SHB research is advised that in the United States, SHB research is distributed by Handelsbanken Markets Securities, Inc., (“HMSI”) an affiliate of SHB. HMSI does not produce research and does not employ research analysts. SHB research and SHB research analysts and its employees are not subject to FINRA’s research analyst rules which are intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. SHB has no affiliation or business or contractual relationship with HMSI that is reasonably likely to inform the content of SHB research reports; SHB makes all research content determinations without any input from HMSI.

SHB research reports are intended for distribution in the United States solely to “major U.S. institutional investors,” as defined in Rule 15a-6 under the Securities Exchange Act of 1934. Each major U.S. institutional investor that receives a copy of research report by its acceptance hereof represents and agrees that it shall not distribute or provide research reports to any other person.

Any U.S. person receiving SHB research reports that desires to effect transactions in any equity securities discussed within the research reports should call or write HMSI. HMSI is a FINRA Member, telephone number (+1-212-326-5153).

[COMPANY NAME]

This report [has/has not] been given to the subject company, or any other external party, prior to publication to approve the accuracy of the facts presented. [Comments received from the subject company have not affected the analyst's recommendation, target price or estimates.]

As of [DD/MM/YYYY]:

- Handelsbanken's analyst [NAME] [has/has no] positions in [COMPANY] or a related instrument.

For more company-specific disclosure texts, please consult the Handelsbanken Capital Markets website: <https://www.researchonline.se/desc/disclosure>.

To find out when a recommendation on a specific company was first published, please consult the Handelsbanken Capital Markets website <https://www.researchonline.se/company>.

On [DD/MM/YYYY] the recommendation [RECOMMENDATION], which was set on [DD/MM/YYYY] at the share price of [SEK XX.XX], was changed to the current recommendation [RECOMMENDATION] at a share price of [SEK XX.XX].